Zambon acquisition of Breath Therapeutics : Italian pharma company Zambon has acquired German biopharma company Breath Therapeutics and its subsidiaries for €140 million, which can potentially go up to total €500 million based on the latter’s achievement of certain regulatory and sales milestones.
Breath Therapeutics, which is based in Munich as well as Menlo Park in California, focuses on developing advanced inhalation therapies for severe respiratory diseases having a high unmet medical need.
Zambon acquisition of Breath Therapeutics, as per the latest pharma acquisition news, is expected to enhance the ability of the two companies in developing treatments for severe respiratory diseases, and also for accelerating the commercialization of their new therapies.
Elena Zambon – President of Zambon, commenting on Zambon acquisition of Breath Therapeutics, said: “It’s a pleasure to welcome in Zambon the Breath Therapeutics team. In a knowledge-based Company, as we are, with a long-term horizon, continuously focused on innovation, the most important asset are our people, their competences and expertise and, above all, their commitment to make patients’ lives better.
“This acquisition is aligned to our core values and our vision to innovate cure and care. We are a “113 year old startup Company”, as I often say, with a strong heritage and tradition, aiming to enrich our pipeline with new relevant research projects to invest in the future for our patients and our people.”
Currently, Breath Therapeutics is engaged in developing L‑CsA‑i, a liposomal formulation of Cyclosporine A, which is being designed for inhaled administration with PARI’s drug-specific, yet-to-be approved customized nebulizer.
The German biopharma company started a couple of phase 3 trials, called BOSTON-1 and -2 across the US and Europe to assess L-CsA-i for the treatment of Bronchiolitis Obliterans Syndrome (BOS), which is considered to be a rare and severe progressive lung disease with no approved treatments as of now.
L-CsA-i has received orphan drug designation for the treatment of Bronchiolitis Obliterans Syndrome from both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).
Results from the L-CsA-i phase 3 clinical trials in 2021. Zambon expects L-CsA-i to be launched by 2023, subject to regulatory approvals from FDA and EMA.
Commenting on Zambon acquisition of Breath Therapeutics, Jens Stegemann – CEO of Breath Therapeutics said: “At Breath Therapeutics, we have established L-CsA-i as a promising therapy for the treatment of BOS, with potential to impact patient lives. In Zambon, an ethical company with a strong heritage of innovation and a genuine commitment to a patient-orientated approach, we have a partner who shares our vision and significantly strengthens our position through their infrastructure, expertise and commitment to R&D.
“Together with the leading international lung transplantation centers participating in our BOSTON pivotal studies, we are now in an excellent position to achieve advances in the treatment of BOS.”
Zambon said that the acquisition of the German biotech company and its L-CsA-i drug candidate complements its existing pipeline in severe respiratory diseases and its presence in US, which includes the treatment of non-cystic fibrosis bronchiectasis (NCFBE), which extend its position in two rare respiratory conditions.
Recently, the Italian pharma company Zambon secured qualified infectious disease product (QIDP)3 and “Fast Track”4 designation from the US FDA for colistimethate sodium powder for nebulizer solution through inhalation, in the prevention of pulmonary exacerbations in adults with NCFBE colonized with Pseudomonas aeruginosa.
For more pharma acquisition news like Zambon acquisition of Breath Therapeutics, keep following Pharma News Daily.